Published: Mar 01, 2021
Company to host conference call today at 8:00 AM Eastern
NEW YORK, March 01, 2021 (GLOBE NEWSWIRE) Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and year ended December 31, 2020.
“The focused execution of the Axsome team made 2020 a year of significant accomplishments. We had successful pre-NDA meetings with the FDA for AXS-05 in major depressive disorder and for AXS-07 in migraine, reported positive results from the pivotal ADVANCE-1 trial of AXS-05 in Alzheimer’s disease agitation, initiated the second pivotal trial of AXS-05 in this indication, received two new FDA Breakthrough Therapy designations, and built out our commercialization infrastructure,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “So far this year, we have submitted to the FDA the NDA for AX
Date Time
What Norway should ask of pharmaceutical industry in Covid-19 pandemic
Norway should take a stronger role not only as a donor, but also as a thought leader on the future of public-private cooperation in global health, argues a new policy brief by the PANPREP project.
Norway has played an important role in global public-private partnerships to fight Covid-19 but has demanded too little, too late of the pharmaceutical industry, says Katerini Storeng.
In February, Norway proposed four ‘principles for urgent pharma action’ through the World Economic Forum. However, Storeng and her team argue that to be effective, Norway’s demands must be much more concrete.
Print article Restaurants, concert venues and airplane manufacturers all stand to benefit from the $1.9 trillion coronavirus relief package the Senate just approved. They are among the few industries that won targeted help in the massive spending bill. Unlike its predecessor - the $2 trillion Cares Act, which proved a smorgasbord for corporate interests - the latest installment of federal aid focuses on funding state and local governments and schools and extra support for individuals. Lawmakers snubbed a wide array of businesses pleading for help from Washington. Gym operators and long-term senior care facilities are among those arguing Congress has left them facing further closures and layoffs even as the broader economic outlook brightens.